SGLT2 Inhibitors in Diabetic Kidney Disease.
作者信息
Zoungas Sophia, de Boer Ian H
机构信息
Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington.
出版信息
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):631-633. doi: 10.2215/CJN.18881220. Epub 2021 Feb 3.
Abstract
摘要
相似文献
1
SGLT2 Inhibitors in Diabetic Kidney Disease.糖尿病肾病中的钠-葡萄糖协同转运蛋白2抑制剂
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):631-633. doi: 10.2215/CJN.18881220. Epub 2021 Feb 3.
2
Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination.慢性肾脏病中的治疗性碳水化合物限制与钠-葡萄糖协同转运蛋白2抑制剂：一种潜在的强效组合。
Diabetes Obes Metab. 2023 Oct;25(10):2791-2794. doi: 10.1111/dom.15195. Epub 2023 Jun 29.
3
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.扩大钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病中的影响
Am J Nephrol. 2024;55(4):417-420. doi: 10.1159/000536540. Epub 2024 Feb 28.
4
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?四种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在2型糖尿病、慢性心力衰竭和慢性肾脏病中是否会带来不同的心肾获益？
Eur J Intern Med. 2021 May;87:98-99. doi: 10.1016/j.ejim.2021.01.009. Epub 2021 Jan 20.
5
SGLT2 inhibitors to prevent diabetic kidney disease.钠-葡萄糖协同转运蛋白2抑制剂用于预防糖尿病肾病。
Lancet Diabetes Endocrinol. 2020 Jan;8(1):4-5. doi: 10.1016/S2213-8587(19)30387-0.
6
DAPA-CKD: Significant Victory for CKD with or without Diabetes.达格列净治疗慢性肾脏病（DAPA-CKD）：无论有无糖尿病的慢性肾脏病的重大胜利。
Trends Endocrinol Metab. 2021 Jun;32(6):335-337. doi: 10.1016/j.tem.2021.02.007. Epub 2021 Mar 4.
7
Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.糖尿病肾病：胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的肾脏保护作用
Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.
8
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.钠-葡萄糖共转运蛋白 2 抑制剂的多效作用：血糖控制以外的肾保护机制。
Int J Mol Sci. 2021 Apr 22;22(9):4374. doi: 10.3390/ijms22094374.
9
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病肾病的肾脏保护作用及其机制。
J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5.
10
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.综述探讨钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病和非糖尿病慢性肾脏病患者中的肾保护机制。
Front Endocrinol (Lausanne). 2023 Dec 20;14:1281107. doi: 10.3389/fendo.2023.1281107. eCollection 2023.
引用本文的文献
1
New Therapies for the Management of Chronic Kidney Disease.慢性肾脏病管理的新疗法
Cureus. 2025 Apr 7;17(4):e81824. doi: 10.7759/cureus.81824. eCollection 2025 Apr.
2
A novel soluble guanylate cyclase activator, avenciguat, in combination with empagliflozin, protects against renal and hepatic injury in diabetic mice.一种新型可溶性鸟苷酸环化酶激活剂阿万西呱与恩格列净联合使用，可预防糖尿病小鼠的肾损伤和肝损伤。
Am J Physiol Endocrinol Metab. 2025 Mar 1;328(3):E362-E376. doi: 10.1152/ajpendo.00254.2024. Epub 2025 Feb 5.
3
International Nephrology Masterclass in Chronic Kidney Disease: Rationale, Summary, and Future Perspectives.国际慢性肾脏病肾病学大师班：基本原理、总结与未来展望。
Life (Basel). 2024 Dec 17;14(12):1668. doi: 10.3390/life14121668.
4
Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂在美国患有和未患有慢性肾病退伍军人中的安全性：一项基于人群的研究。
Lancet Reg Health Am. 2024 Jun 18;36:100814. doi: 10.1016/j.lana.2024.100814. eCollection 2024 Aug.
5
Framework of Guidelines for Management of CKD in Asia.亚洲慢性肾脏病管理指南框架
Kidney Int Rep. 2023 Dec 22;9(4):752-790. doi: 10.1016/j.ekir.2023.12.010. eCollection 2024 Apr.
6
Real-Time Use of SGLT2i Verified in Pre-dialysis: The RSVP Cross-sectional Study.实时使用 SGLT2i 在透析前得到验证：RSVP 横断面研究。
Ann Pharmacother. 2025 Jan;59(1):13-22. doi: 10.1177/10600280241245995. Epub 2024 May 12.
7
Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者心血管疾病管理中的应用：心脏病学入门。
Tex Heart Inst J. 2024 Apr 9;51(1). doi: 10.14503/THIJ-23-8375.
8
SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.SGLT-2 抑制剂可改善 CKD 患者的心血管和肾脏结局：系统评价和荟萃分析。
Sci Rep. 2023 Sep 23;13(1):15922. doi: 10.1038/s41598-023-42989-z.
9
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与慢性肾脏病：你是“列净类药物使用者”吗？
Kidney Med. 2023 Feb 1;5(4):100608. doi: 10.1016/j.xkme.2023.100608. eCollection 2023 Apr.
10
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).慢性肾脏病中的糖尿病管理：美国糖尿病协会（ADA）和改善全球肾脏病预后组织（KDIGO）的共识报告。
Diabetes Care. 2022 Dec 1;45(12):3075-3090. doi: 10.2337/dci22-0027.
Zotero 插件